MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/cbdd.70340

Медицинская библиотека · Chemical biology & drug design · 2026

Cruzain Inhibitors for Chagas Disease: Anticorrelated Optimisation Landscapes and the Multiparametric Path to Clinical Candidates.

Dos Reis Caroline Rodrigues Chaves, de Souza Hellen Valério Chaves Moura, Parra Lidia Corrêa, de Souza Guilber Valério Chaves Moura, Zorzanelli Bruna Costa, Boechat Nubia, Hoelz Lucas Villas Bôas, Fernandes Tácio Vinício Amorim

СтатьяОбзорПеревод в очереди

Аннотация

Over three decades, cruzain, the principal cysteine protease of Trypanosoma cruzi and a validated drug target for Chagas disease, has accumulated 215 inhibitors with IC50 ≤ 1 μM, more than 30 crystal structures, and no clinical candidates. This review argues that the resulting translational paradox reflects not target invalidity, but a persistent strategic mismatch between how cruzain inhibitors have been optimised and what intracellular efficacy requires. Across peptidyl vinyl sulfones, non-peptidic scaffolds, and thiosemicarbazones, enzymatic potency has been systematically prioritised over the coupled determinants of intracellular exposure: permeability, metabolic stability, and cathepsin selectivity. Each inhibitor class fails for a distinct proximal reason, and these failures converge on the same optimisation bias. Computational approaches (docking, molecular dynamics, free-energy perturbation and machine-learning QSAR) have been applied with increasing sophistication, but against affinity-centred objectives that underrepresent exposure constraints. As its principal contribution, this work proposes a multiparametric optimisation framework, provisional viability benchmarks, and a feasibility-envelope concept that reframes cruzain inhibitor discovery as a constraint-satisfaction rather than a potency-maximisation problem. The framework outlines provisional quantitative criteria that a next-generation cruzain lead would likely need to satisfy and explains why structurally tractable intracellular cysteine protease targets can remain clinically unrealised.

Для цитирования: Dos Reis Caroline Rodrigues Chaves, de Souza Hellen Valério Chaves Moura, Parra Lidia Corrêa, de Souza Guilber Valério Chaves Moura, Zorzanelli Bruna Costa, Boechat Nubia, Hoelz Lucas Villas Bôas, Fernandes Tácio Vinício Amorim. Cruzain Inhibitors for Chagas Disease: Anticorrelated Optimisation Landscapes and the Multiparametric Path to Clinical Candidates.. Chemical biology & drug design. 2026. DOI: 10.1111/cbdd.70340.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.